<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">OHASHI, YASUKATA</style></author><author><style face="normal" font="default" size="100%">YATABE, MEGUMI</style></author><author><style face="normal" font="default" size="100%">NIIJIMA, DAISUKE</style></author><author><style face="normal" font="default" size="100%">TANI, KENTARO</style></author><author><style face="normal" font="default" size="100%">OGAWA, CHIAKI</style></author><author><style face="normal" font="default" size="100%">YACHI, YUTAKA</style></author><author><style face="normal" font="default" size="100%">KAGOO, TOSHIYA</style></author><author><style face="normal" font="default" size="100%">BOKU, SAIGEN</style></author><author><style face="normal" font="default" size="100%">UENO, HIRONORI</style></author><author><style face="normal" font="default" size="100%">YANO, TAKAHIRO</style></author><author><style face="normal" font="default" size="100%">HIGAI, KOJI</style></author><author><style face="normal" font="default" size="100%">YOKOYAMA, AKIHIRO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2821-2828</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.12108</style></doi><volume><style face="normal" font="default" size="100%">34</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Gastrointestinal toxicity is common in patients receiving common therapy of ixazomib with lenalidomide and low-dose dexamethasone (IRd) for relapsed/refractory multiple myeloma. Here, we investigated the safety and effectiveness of ixazomib dosing schedules. Patients and Methods: We retrospectively evaluated 17 consecutive patients treated with IRd (10 patients on ixazomib dose-escalation strategy (2.3 mg starting dose); seven patients on standard dose). Results: The incidence of grade 3 or more haematological and grade 2 or more non-haematological adverse events was lower in the dose-escalation group than in the standard-dose group, and only that of diarrhoea was significantly lower. The median time to treatment interruption was significantly longer in the dose-escalation group than in the standard-dose group. There was no significant difference in the overall response rate (20% vs. 43%) and disease control rate (70% vs. 86%). Conclusion: A dose-escalation strategy to optimise ixazomib dosing may reduce treatment interruption due to adverse events without compromising its antitumor activity.</style></abstract></record></records></xml>